Silodosin
- TRADE NAMES: Rapaflo (Watson); Urief (Kissei)
- INDICATIONS: Benign prostatic hyperplasia
- CLASS: Adrenergic alpha-receptor antagonist
- HALF-LIFE: 4.7–6 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alpha blockers, Antihypertensives, Atorvastatin, Clarithromycin, Conivaptan, Cyclosporine, Darunavir, Delavirdine, Diltiazem, Erythromycin, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Ritonavir, Stong CYP3A4 inhibitors, Telithromycin, Vasodilators, Verapamil, Voriconazole
PREGNANCY CATEGORY: B
Not indicated for use in women
Contra-indicated in patients with severe hepatic or renal impairment.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric